Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBS | P35520 | 1/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.78 |
| ▸ | CA12 | O43570 | 3/20 | 0.73 |
| ▸ | CA4 | P22748 | 3/20 | 0.73 |
| ▸ | CA7 | P43166 | 3/20 | 0.73 |
| ▸ | CA2 | P00918 | 2/20 | 0.73 |
| ▸ | RPS6KA3 | P51812 | 7/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.68 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.68 |
| ▸ | NQO2 | P16083 | 1/20 | 0.67 |
| ▸ | TYR | P14679 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24464006 | 1.00 | CBS (0.88) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL161773 | 1.00 | CBS (0.88) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL29753914 | 1.00 | CBS (0.88) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL16131011 | 0.94 | CBS (1.00) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL13973879 | 0.94 | CBS (1.00) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL13963385 | 0.94 | CBS (1.00) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL29380642 | 0.91 | CYP3A4 (0.83) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL572336 | 0.88 | CYP3A4 (1.00) | CBSCYP3A4RPS6KA3CYP2D6RPS6KA1 | |
| SCHEMBL30445487 | 0.86 | CA12 (0.81) | CBSCYP3A4CA12CA4CA7 | |
| SCHEMBL31402522 | 0.86 | CA12 (0.86) | CBSCYP3A4CA12CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344567-B2 | Methods of treating cancer using platanoside and isomers thereof | SHARE GAL RESEARCH AND DEVELOPMENT LTD (IL) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344567-B2 | Methods of treating cancer using platanoside and isomers thereof | EPHB3, EPHB1, FOLR1 | CBS 2108/4885CYP3A4 238/4885CA12 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.